Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (616)	3/8/1999 8:34:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1386

There was discussion of Anat Biegon's departure in the conference call. Harry Tracey (Neuroinvest) asked about the impact of her departure. She was the heart and soul of the Dexanabinol project. Gad answered that now that Dexanabinol was past research and now into development different expertises and skills were required. Bob Cook indicated that this was her decision. George Fink has moved to Israel and is now a full time employee of Pharmos. I have to admit that the idea of Dexanabinol without Anat Biegon is to me like the light bulb without Edison. I suppose GE does light bulbs quite well without him and PARS will do HU-211 well without her. But, it's always sad to see a guiding light depart. John de C